CSafe, a Monroe, Ohio-based provider of temperature-controlled shipping solutions for pharmaceuticals, announced Tuesday it would be joining BioLife Solutions, Inc., in a new partnership for a combined global service network supporting cell and gene therapy (CGT) products.
BioLife is a leading supplier of class-defining bioproduction tools and services for cell and gene therapy out of Bothell, Washington. Together, the two companies will provide cold chain solutions using the evo(R) cold chain management platform, officials said.
“CSafe is honored to partner with the team at BioLife Solutions, whose range of CGT bioproduction tools and services is peerless in the market. We are excited to merge these exceptional tools and services with our expertise in global, reliable scaled delivery,” CSafe CEO Patrick Schafer said. “CGT is hitting its stride and needs global support. We know how important these therapies are to patients everywhere, and it’s our mission at CSafe to protect every shipment.”
By joining BioLife’s global partner network, CSafe will bring its highly reliable global reach to the CGT sector, officials said. BioLife expects to support 10,000-20,000 evo shipments of CGT starting materials and doses over the next year. The partnership between CSafe and BioLife will expand supply chain options for CGT products throughout the product’s development, officials said. CSafe previously worked with biopharmaceutical manufacturers to find shipping solutions for six billion doses of a COVID-19 vaccine.
“We’re excited to work with a global partner with a strong history of reliability and performance and a deep dedication to innovative therapies,” BioLife Solutions CEO Mike Rice said. “We have the best LN2 technology and cGMP storage facilities in the market, in addition to our other world-class CGT solutions, and we are confident our collaboration with CSafe will extend our reach and result in even more reliability and real-time service for CGT partners.”